Invasight

Invasight AG Focuses on Advanced Targeted Therapies for Aggressive Cancers. Headquartered in Zurich, the biotech company has developed groundbreaking technology to discover and develop first-in-class therapies, including ACINDA, which enables the precise design of small molecule inhibitors to target proteins responsible for cancer cell invasion. A key advancement of the company is its protein-protein interaction antagonists, which combine potent anti-tumor activity with promising safety profiles for cancer patients.